Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNT Allient	$38.59 -1.1%	$32.92	$16.91 ▼ $40.00	$660.73M	1.51	117,566 shs	112,225 shs
EYPT Eyepoint Pharmaceuticals	$10.36 -6.3%	$8.01	$3.91 ▼ $13.99	$761.05M	1.67	818,761 shs	903,298 shs
KEQU Kewaunee Scientific	$59.14 +1.1%	$42.27	$30.33 ▼ $71.33	$172.40M	0.7	22,825 shs	9,667 shs
LAB Standard BioTools	$1.32 -2.2%	$1.13	$0.92 ▼ $2.41	$512.76M	1.54	1.95 million shs	1.90 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNT Allient	-1.13%	-0.44%	+11.05%	+84.64%	+56.23%
EYPT Eyepoint Pharmaceuticals	-6.33%	+5.35%	+17.59%	+92.57%	+19.22%
KEQU Kewaunee Scientific	+1.09%	+0.34%	+49.91%	+77.92%	+36.71%
LAB Standard BioTools	-2.22%	-1.86%	+22.22%	+14.78%	-25.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALNT Allient	2.4426 of 5 stars	1.3	3.0	1.7	2.7	2.5	1.9
EYPT Eyepoint Pharmaceuticals	2.5319 of 5 stars	3.5	3.0	0.0	2.5	1.7	0.0
KEQU Kewaunee Scientific	2.0843 of 5 stars	0.0	4.0	0.8	2.3	1.7	1.3
LAB Standard BioTools	3.5586 of 5 stars	3.3	4.0	0.0	3.3	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNT Allient	2.50	Moderate Buy	$31.00	-19.67% Downside
EYPT Eyepoint Pharmaceuticals	3.00	Buy	$25.67	147.75% Upside
KEQU Kewaunee Scientific	0.00	N/A	N/A	N/A
LAB Standard BioTools	2.50	Moderate Buy	$2.50	89.39% Upside

Current Analyst Ratings Breakdown

Latest KEQU, EYPT, ALNT, and LAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	EYPT Eyepoint Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$28.00
5/29/2025	EYPT Eyepoint Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
5/16/2025	EYPT Eyepoint Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $26.00
5/8/2025	EYPT Eyepoint Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$33.00 ➝ $27.00
5/5/2025	ALNT Allient	Northland Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$35.00
5/5/2025	ALNT Allient	Northland Capmk Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/5/2025	ALNT Allient	Northland Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform

(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNT Allient	$529.97M	1.23	$3.00 per share	12.86	$15.72 per share	2.45
EYPT Eyepoint Pharmaceuticals	$43.27M	16.47	N/A	N/A	$4.93 per share	2.10
KEQU Kewaunee Scientific	$240.47M	0.73	$7.43 per share	7.96	$23.21 per share	2.55
LAB Standard BioTools	$174.43M	2.87	N/A	N/A	$1.27 per share	1.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNT Allient	$13.17M	$0.59	65.41	21.09	N/A	1.90%	8.45%	3.86%	8/6/2025 (Estimated)
EYPT Eyepoint Pharmaceuticals	-$130.87M	-$2.41	N/A	N/A	N/A	-261.91%	-54.27%	-41.75%	8/6/2025 (Estimated)
KEQU Kewaunee Scientific	$11.40M	$3.83	15.44	∞	N/A	4.74%	26.02%	9.87%	9/9/2025 (Estimated)
LAB Standard BioTools	-$138.88M	-$0.35	N/A	N/A	N/A	-78.24%	-22.44%	-16.74%	7/30/2025 (Estimated)

Latest KEQU, EYPT, ALNT, and LAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	ALNT Allient	$0.48	N/A	N/A	N/A	$132.89 million	N/A
8/6/2025	Q2 2025	EYPT Eyepoint Pharmaceuticals	-$0.67	N/A	N/A	N/A	$6.82 million	N/A
7/30/2025	Q2 2025	LAB Standard BioTools	-$0.04	N/A	N/A	N/A	$39.83 million	N/A
6/25/2025	Q4 2025	KEQU Kewaunee Scientific	N/A	$1.95	N/A	$1.63	N/A	$77.15 million
5/7/2025	Q1 2025	ALNT Allient	$0.33	$0.46	+$0.13	$0.21	$125.00 million	$134.62 million
5/7/2025	Q1 2025	EYPT Eyepoint Pharmaceuticals	-$0.65	-$0.65	N/A	-$0.65	$8.84 million	$24.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNT Allient	$0.12	0.31%	N/A	20.34%	N/A
EYPT Eyepoint Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KEQU Kewaunee Scientific	N/A	N/A	N/A	N/A	N/A
LAB Standard BioTools	N/A	N/A	N/A	N/A	N/A

Latest KEQU, EYPT, ALNT, and LAB Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/7/2025	ALNT Allient	quarterly	$0.03	0.4%	5/22/2025	5/22/2025	6/5/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNT Allient	0.81	4.03	2.35
EYPT Eyepoint Pharmaceuticals	N/A	7.85	7.79
KEQU Kewaunee Scientific	0.92	2.20	1.59
LAB Standard BioTools	N/A	6.12	5.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNT Allient	61.57%
EYPT Eyepoint Pharmaceuticals	99.41%
KEQU Kewaunee Scientific	32.69%
LAB Standard BioTools	53.74%

Insider Ownership

Company	Insider Ownership
ALNT Allient	15.60%
EYPT Eyepoint Pharmaceuticals	4.46%
KEQU Kewaunee Scientific	14.20%
LAB Standard BioTools	23.16%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNT Allient	2,525	16.93 million	14.29 million	Optionable
EYPT Eyepoint Pharmaceuticals	120	68.81 million	65.74 million	Optionable
KEQU Kewaunee Scientific	1,239	2.95 million	2.53 million	Not Optionable
LAB Standard BioTools	620	379.82 million	291.86 million	Optionable

KEQU, EYPT, ALNT, and LAB Headlines

Recent News About These Companies

Standard BioTools Inc. (NASDAQ:LAB) Stock Holdings Decreased by Sumitomo Mitsui Trust Group Inc.

July 4, 2025 | marketbeat.com

Standard BioTools (NASDAQ:LAB) Stock Price Down 3.3% - Time to Sell?

July 3, 2025 | marketbeat.com

Standard BioTools (NASDAQ:LAB) Stock, Insider Trading Activity

June 24, 2025 | benzinga.com

Illumina to Buy SomaLogic for Up to $425 Mln

June 23, 2025 | marketwatch.com

SomaLogic Acquisition Worth $350 Million Marks Next Step In Illumina's Advanced Biomarker Push

June 23, 2025 | benzinga.com

Standard BioTools (NASDAQ:LAB) Shares Gap Up - Here's What Happened

June 23, 2025 | marketbeat.com

Standard BioTools Inc. Announces Strategic Sale of SomaLogic to Illumina for Up to $425 Million

June 23, 2025 | quiverquant.comQ

Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy

June 23, 2025 | prnewswire.com

Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina

June 23, 2025 | globenewswire.com

With 48% stake, Standard BioTools Inc. (NASDAQ:LAB) seems to have captured institutional investors' interest

June 18, 2025 | finance.yahoo.com

Standard BioTools: Too Early To Determine The Fate Of This Turnaround

June 4, 2025 | seekingalpha.com

Standard BioTools to Host Inaugural “Proteomics Roundtable” Webcast Series

May 30, 2025 | globenewswire.com

Insider Selling: Standard BioTools Inc. (NASDAQ:LAB) SVP Sells 12,536 Shares of Stock

May 24, 2025 | insidertrades.com

Standard BioTools Inc.: Standard BioTools Reports First Quarter 2025 Financial Results

May 10, 2025 | finanznachrichten.de

Standard BioTools Inc. Earnings Call: Mixed Outlook Amid Challenges

May 7, 2025 | tipranks.com

Standard BioTools outlines $165M-$175M revenue target for FY2025 while driving proteomics partnerships

May 6, 2025 | msn.com

Standard BioTools Inc. (LAB) Q1 2025 Earnings Conference Call Transcript

May 6, 2025 | seekingalpha.com

Standard BioTools Inc. 2025 Q1 - Results - Earnings Call Presentation

May 6, 2025 | seekingalpha.com

Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates

May 6, 2025 | zacks.com

Standard BioTools Reports First Quarter 2025 Financial Results

May 6, 2025 | globenewswire.com

Standard BioTools Q1 2025 Earnings Preview

May 5, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KEQU, EYPT, ALNT, and LAB Company Descriptions

Allient NASDAQ:ALNT

$38.59 -0.44 (-1.13%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$38.24 -0.35 (-0.91%)

As of 07/11/2025 07:34 PM Eastern

Allient Inc., together with its subsidiaries, designs, manufactures, and sells precision and specialty controlled motion components and systems for various industries in the United States, Canada, South America, Europe, and Asia-Pacific. It offers brush and brushless DC motors, brushless servo and torque motors, coreless DC motors, integrated brushless motor-drives, gearmotors, gearing, modular digital servo drives, motion controllers, optical encoders, active and passive filters, input/output modules, industrial communications gateways, light-weighting technologies, and other controlled motion-related products, as well as nano precision positioning systems, servo control systems, and digital servo amplifiers and drives. The company sells its products to end customers and original equipment manufacturers in vehicle, medical, aerospace and defense, and industrial markets through direct sales force, authorized manufacturers' representatives, and distributors. The company was formerly known as Allied Motion Technologies Inc. and changed its name to Allient Inc. in August 2023. Allient Inc. was incorporated in 1962 and is headquartered in Amherst, New York.

Eyepoint Pharmaceuticals NASDAQ:EYPT

$10.36 -0.70 (-6.33%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$10.33 -0.03 (-0.25%)

As of 07/11/2025 07:56 PM Eastern

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Kewaunee Scientific NASDAQ:KEQU

$59.14 +0.64 (+1.09%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$58.65 -0.49 (-0.83%)

As of 07/11/2025 07:55 PM Eastern

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. The company operates through two segments, Domestic and International. Its products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks. The company's laboratory products are used in chemistry, physics, biology, and other general science laboratories in the pharmaceutical, biotechnology, industrial, chemical, commercial, educational, government, and health care markets; and technical products are used in facilities manufacturing computers and light electronics and by users of computer and networking furniture. It sells its products primarily through dealers, its subidiaries, and a national distributor. The company was founded in 1906 and is headquartered in Statesville, North Carolina.

Standard BioTools NASDAQ:LAB

$1.32 -0.03 (-2.22%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$1.34 +0.02 (+1.89%)

As of 07/11/2025 07:40 PM Eastern

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time